Signifor LAR Signifor

Support Icon

Contact a Recordati Rare Diseases Representative

Target the source

SIGNIFOR LAR is the first and only long-acting, pituitary-targeted therapy for Cushing’s disease with proven clinical efficacy.2,3

SIGNIFOR LAR targets the receptors most responsible for ACTH oversecretion to help settle the storm of cortisol overproduction.1


Icon representing HCP

SIGNIFOR LAR is a long-acting intramuscular injection given by a trained healthcare professional once every 4 weeks (28 days).1

Resources for you
and your patient

ACTH=adrenocorticotropic hormone.

References: 1. SIGNIFOR® LAR (pasireotide) for injectable suspension, for intramuscular use [full prescribing information]. Lebanon, NJ: Recordati; March 2020. 2. Ciato D, et al. Expert Opin Investig Drugs. 2017;26(1):75-84. 3. Langlois F, et al. Front Endocrinol. 2018;9(164)1-12.

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Important Safety Information

Warnings and Precautions

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Females and Males of Reproductive Potential